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Abstract
Background: Accurate, inexpensive point-of-care CD4+ T cell testing technologies are needed that can deliver CD4+ T cell
results at lower level health centers or community outreach voluntary counseling and testing. We sought to evaluate
a point-of-care CD4+ T cell counter, the Pima CD4 Test System, a portable, battery-operated bench-top instrument that is
designed to use finger stick blood samples suitable for field use in conjunction with rapid HIV testing.
Methods: Duplicate measurements were performed on both capillary and venous samples using Pima CD4 analyzers,
compared to the BD FACSCalibur (reference method). The mean bias was estimated by paired Student’s t-test. Bland Altman
plots were used to assess agreement.
Results: 206 participants were enrolled with a median CD4 count of 396 (range; 18–1500). The finger stick PIMA had a mean
bias of 266.3 cells/mL (95%CI 283.4249.2, P,0.001) compared to the FACSCalibur; the bias was smaller at lower CD4
counts (0–250 cells/mL) with a mean bias of 210.8 (95%CI 227.32+5.6, P=0.198), and much greater at higher CD4 cell
counts (.500 cells/mL) with a mean bias of 2120.6 (95%CI 2162.8, 278.4, P,0.001). The sensitivity (95%CI) of the Pima CD4
analyzer was 96.3% (79.1–99.8%) for a ,250 cells/ul cut-off with a negative predictive value of 99.2% (95.1–99.9%).
Conclusions: The Pima CD4 finger stick test is an easy-to-use, portable, relatively fast device to test CD4+ T cell counts in the
field. Issues of negatively-biased CD4 cell counts especially at higher absolute numbers will limit its utility for longitudinal
immunologic response to ART. The high sensitivity and negative predictive value of the test makes it an attractive option for
field use to identify patients eligible for ART, thus potentially reducing delays in linkage to care and ART initiation.
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Introduction
The availability of highly active antiretroviral therapy (ART) to
the developing world has been life-saving and led to remarkable
reversals in mortality rates and opportunistic infection incidence
rates. [1,2] According to the WHO classification adopted by most
countries in Sub-Saharan Africa, clinicians base the decision to
initiate antiretroviral therapy (ART) on CD4+ cell count or WHO
stage IV status criteria. [3] Initiating ART in asymptomatic
patients with higher CD4+ T cell counts who may not qualify by
clinical criteria is also desirable as this avoids both morbidity and
mortality. [4,5] Eligibility for ART is very difficult to assess by
clinical criteria only; many patients eligible by CD4 T cell criteria
may not receive medication if clinical signs and symptoms only are
used. [6,7].
CD4+ T cell counts often need to be done at higher-level health
centers with functional labs and adequate power source, or at
reference regional labs. Because the number of facilities that offer
a CD4+ T cell count is limited, there are often delays in obtaining
the test results and, subsequently, delays in the initiation of ART.
Furthermore, in most ART rollout programs in sub-Saharan
Africa (SSA), viral load testing is not available, and immunologic
monitoring is used instead as part of routine follow-up care.
Even though financial support continues to be a principal factor
in addressing HIV/AIDS related mortality in developing coun-
tries, a more fundamental implementation obstacle is the
inadequate access to basic health services. [8] Due to limited
laboratory capacity, access to diagnostic testing is particularly
inadequate, and is often non-existent in rural settings. [9] Point-of-
care (POC) instruments could provide diagnostic capacity in
resource-limited settings. Accurate, inexpensive point-of-care
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several point-of-care CD4+ T cell platforms that can deliver CD4+
T cell results at lower level health centers or even at community
outreach with voluntary counseling and testing have emerged.
Many of these new POC instruments are battery operated, use
venous and/or finger-stick blood samples and could positively
impact delays in ART initiation. The translational research team
at the Infectious Diseases Institute (IDI) in Kampala Uganda, in
collaboration with the MU-JHU Core Lab at the IDI, evaluated
a point-of-care CD4+ T cell counter, the Pima CD4 Test System,
a portable bench-top instrument that is designed to perform in
laboratory as well in non-laboratory environments.
Methods
Ethics Statement
The protocol was approved by the Scientific Review Committee
of the Infectious Diseases Institute, Joint Clinical Research Center
Institutional Review Board, and the Uganda National Council of
Science and Technology.
Population tested and study design
Patients at the Adult Infectious Diseases Institute (IDI) Clinic
within the Mulago Hospital Complex in Kampala, Uganda were
approached during a routine clinic visit. Patients were invited to
take part in the study and gave written informed consent before
being enrolled. Measurements were performed using a total of 4
Pima CD4 analyzers (Alere Inc.Waltham, Maryland, USA).
Duplicate measurements were performed on both capillary and
venous samples using two different Pima CD4 analyzers. Capillary
samples were obtained by a study nurse; the participant’s finger
was lanced and blood was collected from the finger tip directly into
the cartridge. Venous samples were collected by venipuncture and
stored in an EDTA tube at room temperature. At the time of
analysis (within 6 hours of collection), the tube was inverted 10–15
times before each measurement to ensure proper sample mixing,
and then 10 ml of mixed blood was pipetted into the capillary tube
at the end of the cartridge.
Duplicate measurements on a single venous blood sample were
also performed using the BD FACSCalibur (Becton Dickinson,
CA, USA) as a reference method. Testing on both BD
FACSCalibur instruments was performed within 24 hours of
blood collection. Since the Pima CD4 Test System was strictly for
investigational use, patients’ clinicians were provided only with the
CD4+ T cell results from the FACSCalibur reference method,
while the results of the PIMA analyzers were stored in the study
files.
Pima CD4 system and CD4 enumeration
The self-contained disposable Pima CD4 test cartridge uses an
integrated capillary to capture 5 mL of sample and contains all
dried reagents needed to perform the test. The test is performed
entirely within the cartridge and no part of the Pima Analyzer has
contact with the sample at any time, thus minimizing the risk of
analyzer contamination and sample carry-over. After inserting the
cartridge into the analyzer, the sample is transported by peristaltic
movement into an incubation compartment and allowed to
interact with CD3 and CD4 surface antigens (both carried by T
helper lymphocytes) specific antibodies labeled with PE and PE-
Cy5, respectively. After an automated defined incubation time, the
stained sample is transferred into a reading compartment of the
cartridge. Fluorescence signals from the bound antibodies are then
detected by a CCD camera and analyzed by an on-board,
embedded computer. Results were displayed by the instrument as
the absolute number of cells/mL. Results are also stored and can
be printed any time after the test.
The reference method was the BD FACSCalibur using the
MultiTEST CD3/CD8/CD45/CD4 reagent with TruCOUNT
Tubes, and MultiSET software. These tests were done by
Makerere University-Johns Hopkins University Clinical Core
laboratory, a College of American Pathologists (CAP) certified
laboratory that undergoes external proficiency testing through the
College of American Pathologists and UKNEQAS as well as daily
calibration and internal quality controls.
Statistical Analysis Methods
Data were analyzed using SAS 9.2 software (SAS Institute Inc.
North Carolina, USA). The Pearson Correlation Coefficient was
calculated for each pair of Pima capillary tests or Pima venous tests
and the BD FACSCalibur gold standard tests; the relative
difference analysis was performed for each pair of tests by
Wilcoxon signed-rank test since we could not assume that the
population was normally distributed, and the mean bias was
estimated by paired Student’s t-test. Using the first CD4 count
measurement of each pair, scatter plots and Bland-Altman plots
[10] were used to assess the agreement between the Pima capillary
and the BD FACSCalibur results, and between the Pima venous
and the BD FACSCalibur results.
Results
Characteristics of the study population
Two hundred and six unselected participants were enrolled in
the study between September 7 and November 2, 2009. The
majority were women (156, 75.7%), the median age was 36 years
(range 18–68), and 49% of the patients were WHO stage 3 or 4.
The median absolute CD4+ T cell count by FACSCalibur was
396 (range: 18–1500). 142 (68.9%) were currently on ART.
Performance of Pima CD4 analyzer
Duplicate measurements were performed on venous blood
samples using two different Pima CD4 analyzers on 206
participants. A total of 446 tests were performed; of these, 36
tests (8.1%) generated an error instead of a valid result. Samples
yielding an error instead of a valid result were retested. Four
hundred-ten results (91.93%) were used for statistical analysis.
Duplicate measurements were performed on finger stick samples
again using two different Pima analyzers on only 176 patients due
to errors or refusal to have multiple finger sticks. On capillary
blood, a total of 372 tests were performed; of these, 66 tests
(17.74%) generated an error instead of a valid result. Three
hundred-six results (82.26%) were used for statistical analysis.
Comparison of the Pima capillary and venous testing
methods to BD FACSCalibur
Paired capillary PIMA and FACSCalibur results were com-
pared using Bland-Altman analysis. The plots are shown in
Figure 1. The mean bias of the capillary testing was 266.3 cells/
mL (95%CI 283.4249.2, P,0.001) overall for the 176 paired
samples; the bias was smaller at lower CD4 counts (0–250 cells/
mL) with a mean bias of 210.8 (95%CI 227.32+5.6, P=0.198),
and much greater at higher CD4 cell counts (.500 cells/mL) with
a mean bias of 2120.6 (95%CI 2162.8, 278.4, P,0.001).
(Table 1) The correlation coefficient between 176 capillary and
BD FACSCalibur paired tests was 0.86 (P,0.001).
The comparison of the Pima venous samples compared to the
BC FACSCalibur showed similar results. (Table 1) The mean bias
of the venous testing was 268.5 cells/ml (95%CI 279.6257.4,
Pima CD4 Evaluation
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CD4 counts (0–250 cells/mL) with a mean bias of 13.6 cells/ml
(95%CI 2.52224.7, P=0.02) and much greater at higher CD4 T
cell counts (.500 cells/mL) with a mean bias of 2121.7 (95%CI
2147.9 – 295.4, P,0.001). The correlation coefficient between
206 venous and BD FACSCalibur paired tests was 0.93
(P,0.001). (See Figure 2) Although a simple linear regression
could be fitted with the data, whereby the BD result could be
predicted on the basis of the Pima result, the negative predictive
value of the predicted result decreased compared to the measured
BD value and would not reliably improve the predictive accuracy
of the test.
The Pima venous compared to the Pima capillary testing
showed that the values were similar overall with a mean bias of
23.8 cells/ml (95%CI 217.75, 10.25, P=0.598). The correlation
between the two tests was 0.87 but was not statistically significant
(P=0.39).
Agreement and precision analysis based on duplicate
measurements
Duplicate testing was only possible for 130 patients with Pima
capillary due to the high error rate and the interclass correlation
coefficient between the 2 readings was 0.79. For the venous
samples, there were 204 patients who had 2 duplicate measure-
ments, and all 206 patients had duplicate FACSCalibur samples
(both rho=0.96). Table 2 shows the precision of the duplicate
testing and shows a significant difference in the Pima capillary
duplicates (mean difference 33.869.8 cells/mL, P=0.005), but
acceptable precision for both the Pima venous and BD
FACSCalibur gold standard.
Sensitivity, specificity of venous and capillary samples in
assessing eligibility for ART
We assessed the sensitivity and specificity of the Pima CD4
analyzer using a cut-off of 250 cells/mL and 300 cells/mL. As
shown in Table 3 the sensitivity of the Pima CD4 analyzer was
high for both cut-offs with very high negative predictive values,
making the Pima device an useful tool to identify patients in need
of ART, although some ineligible patients may be referred for
ART.
Discussion
This evaluation of the Pima CD4 point-of-care test shows that
there was significant bias toward lower absolute CD4+ T cell
counts for both venous and capillary finger stick Pima methods in
comparison to the BD FACSCalibur measurement from a CAP
certified lab. The bias was lower at lower absolute CD4+ T cell
Figure 1. Bland Altman analyses of Pima test results compared to BD FASCalibur method. a) Pima capillary samples and, b) Pima venous
samples, versus the BD FACS reference method. Upper and lower lines show 2 standard deviations from the mean (center line).
doi:10.1371/journal.pone.0034319.g001
Table 1. Mean and Median Bias Analysis of Pima Capillary and Venous Measurements.
Comparison
Reference method*
(cells/ml)
Number of
pairs (%) Mean Bias (95%CI) Median Bias (IQR) P-value**
Pima CD4 Capillary Overall 176 266.3(283.4, 249.2) 241.0(2105.0, 4.5) ,0.001
0–250 27 210.8(227.3, 5.6) 26.0 (232.0, 11.0) 0.198
250–500 90 247.3(262.2, 232.5) 240.5 (276, 25.0) ,0.001
.500 59 2120.6 (2162.8, 278.4) 2107.0 (2197.0, 210.0) ,0.001
Pima CD4 Venous Overall 206 268.5 (279.6, 257.4) 254.0 (295.0, 217.0) ,0.001
0–250 35 13.6 (2.5, 24.7) 216.0 (235.0, 21.0) 0.020
250–500 107 254.6 (264.5, 244.7) 253.0 (279.0, 223.0) ,0.001
.500 64 2121.7 (2147.9, 295.4) 293.5 (2167.5, 264.5) ,0.001
*BD FACSCalibur.
**P-value using Wilcoxon Signed Rank Test.
CI=confidence interval, CD4=CD4+ T cell count (cells/mL).
doi:10.1371/journal.pone.0034319.t001
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for longitudinal care and immunological monitoring. Our data
corroborates that of three other studies where the Pima CD
analyzer was less accurate at higher CD4 cell counts, was
consistently negatively biased, although to different degrees
compared to our study. [11,12,13] In the study from Senegal
which also included HIV-negative patients allowing for higher
CD4 ranges, this increasing negative bias and decrease in the %
similarity with FACSCount results with increasing CD4 T cell
counts was particularly evident. The other published study of the
Pima analyzer showed little bias at both high and low CD4+ T cell
counts. [14].
The machine is highly portable, self-contained and battery-
operated and easy to use by most health care worker cadres. [14]
The staff in our study were trained in a single 2 hour session.
Quality control and observed practical training would be required
to ensure that good volume and flow of blood is obtained. Without
this, the accuracy of the test is compromised. As a screening test
for ART eligibility in the field, however, both the venous and Pima
capillary finger stick methods showed good negative predictive
value. This test would identify almost all eligible patients to be
referred at the time of HIV testing, thereby eliminating the delay
between a positive HIV test and CD4+ T cell count testing and
result reporting back to the patient. The literature on outcomes of
HIV/AIDS care programs is often restricted to patients on
antiretroviral therapy. However, patients are often diagnosed with
HIV infection at community-based counseling and testing sites,
and then required to travel to health centers offering HIV care on
at least 2 occasions to get a CD4+ T cell count and receive the
results. Both of these steps have significant potential for delays, loss
to follow-up and death.
Cohorts from South Africa Mozambique, Kenya, and Uganda
have reported on outcomes and waiting times during the interval
between enrollment in an ART program and treatment initiation.
[15,16,17,18,19,20,21] In particular, 2 cohorts from South Africa
and Mozambique demonstrated high rates of lost-to-follow-up
prior to ART initiation. In Durban, South Africa, 45% of persons
registering at an ART clinic with a newly diagnosed HIV infection
were lost to care. [21] In another study of 7,005 newly diagnosed
HIV patients in Mozambique, only 57% registered at an ART
clinic within one month, and 77% of ART clinic registrants
received a CD4+ T cell count test within one month of
registration. Only 49% of those patients who received a CD4+
T cell count initiated treatment; there was a median of 71 days
between receiving their results and starting ART. [19] The Pima
test was recently examined in 929 patients from 4 clinics in
Mozambique randomized to either lab-based CD4 testing (492
participants) or point-of-care Pima CD4 testing (437 participants).
There was a significant decrease in losses to follow up between
enrolment and antiretroviral therapy initiation from 64% to 33%
(adjusted odds ratio [OR] 0.27, 95% confidence intervals [CI]
0.21–0.26). [22]
The finger stick platform is very attractive, but at the time of this
testing still problematic; the number of patients who had errors
with finger stick testing with particular cartridge lots was rate-
limiting. This has also been noted in the studies from both
Thailand and Senegal. [12,13] Since then, the company has made
some modifications of the cartridge including increasing the
concentration of EDTA. If these high error rates are not reduced
in subsequent cartridge models, technician time required to run
a single test would increase as well as the per test cost. In addition,
technicians need to be trained as differences in methods of
elucidating finger stick blood can lead to differences in the
measured values of CD4 because the test measures absolute values
rather than percentages. Although we consistently saw negative
bias accentuated at higher CD4 T cell counts, a study in South
Africa reported negative bias with decreased precision (greater
variation) with capillary sampling which was operator-dependent
and particularly pronounced in clinics with less laboratory
capacity. [23] The quality of the capillary blood flow was a notable
issue; in order to establish an adequate amount of blood at a fast
enough rate to fill the capillary tube on the cartridge, a larger
lancet is recommended. Another limitation of the device is that
Figure 2. Comparison of Pima CD analyzer capillary samples testing (a) and venous samples testing (b) compared to BD FACS
reference method.
doi:10.1371/journal.pone.0034319.g002
Table 2. Precision of duplicate testing for all 3 methods.
Test Type
Number
of pairs
Mean
Difference 95% CI P-value*
Pima
Capillary
130 33.38 14.19, 52.57 0.005
Venous 204 26.54 213.69, 0.61 0.099
BD FACS
Venous
206 1.87 26.77, 10.51 0.899
Using Wilcoxon Signed Rank Test;
CI =Confidence Interval.
doi:10.1371/journal.pone.0034319.t002
Pima CD4 Evaluation
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prevalence of HIV at the test site, the CD4 testing could become
rate limiting.
In summary, the Pima CD4 finger stick test is an easy-to-use,
portable, relatively fast device to test CD4+ T cell counts in the
field. Issues of negatively-biased CD4 cell counts especially at
higher absolute numbers will limit its utility for longitudinal
immunologic response to ART. The high sensitivity and negative
predictive value of the test makes it an attractive option for field
use to identify patients eligible for ART, thus reducing delays in
linkage to care and potentially ART initiation. Further studies to
examine the impact of Pima on field HIV-tested patients and
subsequent ART referral patterns is warranted.
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